Entering Bangladesh as an International Chemical or Pharma Innovator

Bangladesh is among the fastest-growing healthcare and industrial markets in South Asia — yet regulatory complexity, distributor fragmentation, and credit risk make solo market entry costly. Inventa acts as the exclusive licensing partner and registered MAH for international principals who want speed without sacrificing compliance.

Five decision criteria for principals

1. Regulatory pathway: CTD dossier readiness, BE studies, and DGDA classification timelines.
2. Commercial infrastructure: Hospital listing, tender participation, and field force coverage.
3. Supply chain: GSDP warehousing, cold-chain capability, and import block management.
4. Local risk absorption: Credit terms, pharmacovigilance liability, and product liability insurance.
5. Exit flexibility: Clear KPIs and transfer protocols if partnership terms change.

Our market-entry workstreams typically run 6–9 months from term sheet to first commercial shipment.